Regenxbio Inc. (RGNX) Stock Price Down 2.9%
Regenxbio Inc. (NASDAQ:RGNX) shares dropped 2.9% on Monday . The stock traded as low as $7.57 and last traded at $7.67, with a volume of 66,961 shares changing hands. The stock had previously closed at $7.90.
RGNX has been the topic of several research analyst reports. Morgan Stanley increased their price target on shares of Regenxbio from $34.00 to $36.00 in a report on Friday, April 8th. Zacks Investment Research cut shares of Regenxbio from a “hold” rating to a “sell” rating in a report on Tuesday, March 22nd. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a report on Tuesday, May 10th. Finally, Piper Jaffray Cos. reissued a “buy” rating and issued a $33.00 price target on shares of Regenxbio in a report on Tuesday, July 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $28.35.
The stock has a 50-day moving average price of $9.74 and a 200 day moving average price of $11.60. The firm’s market cap is $202.01 million.
Regenxbio (NASDAQ:RGNX) last issued its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by $0.01. Equities research analysts expect that Regenxbio Inc. will post ($2.37) earnings per share for the current year.
In other news, insider Fmr Llc sold 20,558 shares of Regenxbio stock in a transaction dated Friday, April 22nd. The shares were sold at an average price of $11.30, for a total transaction of $232,305.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.